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Abstract 
Extracellular vesicles, including exosomes, are naturally derived nanovesicles generated in 
and released by numerous cell types. As extracellular entities they have the capacity to 
interact with neighbouring cells and distant tissues and affect physiological processes as 
well as being implicated in numerous diseases including tumorigenesis and 
neurodegeneration. They are also under intense investigation as delivery vectors for 
biotherapeutics. The ways in which EVs interact with recipient cells to influence cell 
physiology and deliver a macromolecular payload are at the early stages of exploration. A 
significant challenge within these studies is the ability to label EVs directly or indirectly with 
fluorescent probes to allow visualization without compromising functionality. Here, we 
present a thiol-based fluorescence labelling method allowing comprehensive analysis of the 
cellular uptake of prostate cancer derived EVs in live cells using confocal microscopy.  
Labelling of the EVs in this way did not influence their size and had no effect on their ability 
to induce differentiation of lung fibroblasts to myofibroblasts. For endocytosis analyses, 
depletion of key endocytic proteins and the use of chemical inhibitors (Dynasore, EIPA, 
Rottlerin and IPA-3) indicated that fluid-phase endocytosis and/or macropinocytosis was 
involved in EV internalisation. Over a period of six hours EVs were observed to increasingly 
co-localise with lysosomes, indicating a possible termination point following internalisation. 
Overall this method provides new opportunities for analysing the cellular dynamics of EVs as 
biological entities affecting cell and whole body physiology as well as investigating their 
potential as drug delivery vectors.  
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1 Introduction 
Exosomes, a subpopulation of extracellular vesicles (EVs), are secreted 30-150 nm sized 
vesicles manufactured within multivesicular endosomes and trafficked to the extracellular 
space through Rab-GTPase dependent mechanisms 1, 2. These structures comprise a 
phospholipid bilayer that is particularly enriched in membrane proteins such as 
tetraspanins, MHC Class-I proteins, integrins and many others 3, 4. The vesicle lumen also 
encompasses complex entities derived from the cell of origin, including cytosolic proteins 
and a subset of cellular RNAs 5, 6. Exosomes naturally serve as a means of shuttling this cargo 
intercellularly as a mode of communication, which can modulate important physiological 
and pathological processes such as cancer, cardiovascular diseases, and neurodegeneration, 
as well as in transfer of pathogenic virulence factors 6. 
This natural ability to functionally transfer a spectrum of macro-molecular cargo between 
cells raises opportunities for exploiting exosomes as vectors for drug delivery 7, 8. However, 
little is known about the ways in which exosomes initially interact with the cell, gain 
intracellular access and are trafficked through the cell to their final destination. Even less is 
known about how intravesicular cargo is released and directed towards the intended target 
within the cytosol or other intracellular compartments. The capacity of exosomes to 
mediate these effects, possibly through endocytosis, requires further characterisation in 
order to fully understand their natural roles in disease pathogenesis and also unlock their 
potential for drug delivery.  
Endocytosis involves the envelopment of materials from the exterior region of the cell by 
the plasma membrane. Several endocytic pathways have now been described, each utilising 
proteins that regulate single and multiple uptake routes 9, 10. Clathrin-mediated endocytosis 
is by far the most well-defined mechanism, characterised by the formation of a clathrin 
coated pit that eventually buds into the cytoplasm to form a clathrin coated vesicle that is 
uncoated before fusing with an early or sorting endosome 9-11. Endocytosis mediating from 
distinct platforms of the plasma membrane termed lipid rafts has also been described, with 
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these processes demonstrating involvement of Caveolin-1 9, 12 or Flotillin-1 9, 13. Other 
pathways include fluid-phase endocytosis and macropinocytosis, which are defined as cargo 
non-specific mechanisms, with the latter process demonstrating a reliance on extensive 
plasma membrane reorganisation by the actin cytoskeleton.  This is often in response to 
growth factor stimulation 14-16. Distinguishing between macropinocytosis and fluid phase 
uptake as constitutive processes is very difficult as they may share similar protein 
mediators.  Proteins that have been implicated in the organisation of macropinocytosis 
include PAK-1 and Cdc42 that function as actin regulators 17-19.  
Exosome entry and cargo release has been proposed to occur via endocytosis 20 and/or 
through direct exosome-plasma membrane fusion 21; reviewed in 22. These studies labelled 
purified exosome preparations with fluorescent probes and then used either microscopy or 
flow cytometry to monitor cell interaction and uptake. Labelling strategies include the use 
of lipophilic dyes such as PKH26 23, 24 and the carbocyanine dyes (DiI, DiO) 25, 26, which 
embed non-covalently within the membrane bilayer of the exosome. Such dyes can 
however form dye aggregates or micelles in aqueous solutions, of similar proportions to 
exosomes, potentially giving misleading information in uptake experiments 27. Exosome 
permeable compounds including carboxyfluorescein succinimidyl ester (CFSE) and 5(6) 
carboxyfluorescein succinimidyl diacetate (CFDA) have also been used for this purpose 20, 28. 
Any structural modifications on exosomes following labelling with these dyes will alter their 
physical characteristics but may also affect their functional properties. For cell uptake 
analysis this functional impact is rarely considered.  Other labelling methods include the use 
of stable cell lines that fuse Green Fluorescent protein (GFP), or variants of, on to a protein 
enriched in exosomes, such as the tetraspanin CD63. This consequently produces a sub-
population of exosomes, of uncertain proportion, that are GFP-tagged 29, 30. This approach 
also produces cells overexpressing tetraspanins; proteins that are known to be important in 
the biogenesis and function of these vesicles 31, and this is therefore a major modification of 
the composition of the vesicles being produced.  Furthermore, tetraspanins are also present 
on linear membrane fragments, various forms of cellular debris and larger plasma-
membrane derived vesicles, and hence does not entirely alleviate the need for rigorous 
exosome-purifications.  
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In this report, we have developed a simple and rapid method for covalent fluorescent 
labelling of purified EVs. The method takes advantage of thiol (sulph-hydryl) groups on the 
EV surface and our labelling approach does not alter their documented capacity to induce 
fibroblast differentiation in vitro 32, 33; suggesting they retain at least a fraction of their 
biological effects. We thereafter investigated the potential pathways involved in EV uptake, 
using the well characterised endocytic HeLa cell model. This was performed with chemical 
inhibitors of endocytic pathways or siRNA-based depletion of specific endocytosis regulating 
proteins, and thus pathways 34. Our findings show that EV uptake is clathrin-independent, 
with an endocytic profile indicative of macropinocytosis with eventual delivery to 
lysosomes.  
2 Materials and Methods 
2.1 Reagents 
Transferrin Alexa488 (Tf488), Alexa488/647 10kDa dextran (Dx488/647), C5-maleimide-
Alexa488/633, Cell Mask Deep Red Plasma Membrane Stain, DulďeĐĐo͛s Modified Eagle 
Medium (DMEM), Oligofectamine, Opti-MEM I reduced serum medium were purchased 
from Invitrogen (Paisley, U.K.). Bovine serum albumin (BSA), Dynasore, 5-(N-Ethyl-N-
isopropyl) amiloride (EIPA), ϭ,ϭ′-Disulfanediyldinaphthalen-2-ol (IPA-3) and Rottlerin were 
obtained from Sigma-Aldrich (Dorset, U.K.). Complete mini-protease inhibitor cocktail 
tablets were purchased from Roche Diagnostics (Sussex, U.K.). Single sequence (21-23 
residues) siRNAs listed in Table 1 were purchased from Eurofins MWG Operon (Ebesburg, 
Germany). Sucrose and D2O for EV isolations were from Sigma-Aldrich and Optiseal™ 
ultracentrifugation tubes from Beckman Coulter.  
Table 1. siRNA sequences used to deplete key endocytic proteins  
siRNA Target Sequence Reference 
AP2μ2 GUGGAUGCCUUUCGGGUCAdTdT Custom designed 
Cav-1 AGACGAGCUGAGCGAGAAGdTdT 34 
Cdc42 GACUCCUUUCUUGCUUGUUdTdT Custom designed 
Flot-1 UGAGGCCAUGGUGGUCUCCdTdT Custom designed 
PAK1 AUAACGGCCUAGACAUUCAdTdT 34 
GFP GGCUACGUCCAGGAGCGCAdTdT 34 
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2.2 Cell culture 
All culture materials were purchased from Invitrogen (Paisley, U.K.). DU145 prostate cancer 
cells (ATCC) were maintained in Integra Bioreactors (CellLine 1000AD) as described 35 with 
the outer chamber housing RPMI and 5% foetal calf serum (FCS), with the inner cell-
containing chamber holding RPMI with 5% FCS that has previously been made devoid of 
bovine EVs by overnight ultracentrifugation and filtration. All were cultured in a humidified 
incubator at 5% CO2, 37°C. Primary lung fibroblasts (AG02262, Coriell Institute of Medical 
Research) were cultured as sub-confluent monolayers in DMEM F-12 (1:1 mix) 
supplemented with 10% EV-depleted FCS.  HeLa cervical cancer cells (CCL-2; ATCC, 
Teddington, UK) were maintained in sensi-cell MEM medium supplemented with 10% FCS, 
as a sub-confluent monolayer.  
 
2.3  Antibodies 
Listed antibodies were from the following manufacturers: AP50 (AP2µ2) and flotillin-1 BD 
Transduction Laboratories (Oxford, U.K.); Caveolin-1, GAPDH, PAK-1 Cell Signalling 
Technologies (Hertfordshire, U.K.); Anti-TSG101, Alix, Calnexin (Santa Cruz Biotechnology, 
Dallas, TX, USA); anti MHC Class-I (eBioscience, ThermoFisher Scientific, Paisley, UK). Anti-
Cdc42 and horseradish peroxidase (HRP) -anti-δ-tubulin (Sigma-Aldrich, Dorset, U.K.); 
Secondary HRP conjugated goat anti-mouse/anti-rabbit (Thermo-Scientific Pierce, 
Loughborough, U.K.). 
 
2.4 Extracellular vesicle isolation, purification and characterisation 
Using the methodology outlined in Supplementary Information, the isolation and 
subsequent analyses satisfy the criterion set by the International Society for Extracellular 
Vesicles (ISEV), for defining this specimen as exosomes 36. However, as discussion continues 
within the field on isolation and characterisation of exosomes as pure entities we refer here 
on in to our purified particles as EVs. 
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2.5 Labelling of extracellular vesicles with Alexa488/633 
C5-maleimide-Alexa488 or C5-maleimide-Alexa633 (ϮϬϬ μg/ŵl - 2.5 µl) was added to a 30 μl 
EV aliquot containing 60 to 100 µg protein, aŶd ŵade up to ϱϬ μl ǁith PBS before 
incubation, with no agitation, for 60 min in the dark at room temperature (R/T). During 
incubation exosome spin columns (Invitrogen) were prepared according to manufacturer͛s 
instructions and powdered resin was hydrated for 15-30 min at R/T. Spin columns placed in 
the collection tubes were centrifuged for 2 min (750 x g), in a swing-out rotor. The collection 
tubes were discarded before the addition of the labelled EV aliquot to the resin. Columns 
were placed in 1.5 ml eppendorf tubes and centrifuged for 3 min (750 x g) to collect labelled 
EVs. Non-incorporated, excess dye was retained by the resin, and controls involving dye but 
no EVs were performed in parallel to confirm dye retention by the column. For microscopy 
analysis, labelled EVs (referred to as EV488 or EV633) were gently mixed to 1000 μl iŶ 
phenol red free DMEM, before filtration through a Ϭ.ϮϮ μŵ filter (Millex), aliquoted and 
stored at -80°C until required. 
 
2.6  Fibroblast differentiation assay 
To test the impact of labelling on EV function, we used a well-established fibroblast 
differentiation assay as described 33. Briefly, 80% confluent primary lung fibroblasts (Coriell 
Institute for Medical Research) were serum deprived for 72 h prior to stimulation with 
native or fluorescently labelled DU145 EVs (at 200 µg/ml). This dose provides vesicle-
associated TGF equivalent to a dose of 1.5 ng/ml of soluble TGF. As a positive control, 
soluble rhTGF (Promocell) was used at 1.5 ng/ml. After 72 h, ice cold acetone: methanol 
(1:1 ratio) was added as fixative for 5 min. Following solvent evaporation in air, cells were 
blocked in 1% BSA/PBS for 1 h. Monoclonal antibody against alpha-smooth muscle 
actinSMA) (Santa Cruz Biotechnology, Dallas, TX, USA) followed by secondary goat anti-
ŵouse IgG Faď͛-Alexa594 conjugate (ThermoFisher Scientific) was used to visualise onset of SMA stress-fibres. This is a hallmark of the myofibroblastic phenotype visualised by 
fluorescence microscopy (Zeiss Observer, Cambridge, UK). Fibroblast secretion of 
Hepatocyte Growth Factor (HGF) was assessed by DuoSet ELISA (R&D Systems), performed 
on fibroblast conditioned medium 72 h post-treatment, following manufacturers protocol. 
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2.7 Cell internalisation of Alexa488 labelled extracellular vesicles in HeLa and primary lung 
fibroblasts 
Cells were seeded in 35 mm MatTek imaging dishes (MatTek Corporation, MA, USA) and 
cultured for 24 h to reach 80-90% confluency. On the day of the experiment, EVs in imaging 
medium (phenol-red free DMEM, 20 mM HEPES) containing 0.05% w/v BSA were added to 
cells at 50-60 µg/ml for 30-360 min before live cell confocal microscopy was performed. 
Cells were incubated with the nuclear label Hoechst for 5 min before washing with imaging 
medium followed by imaging. For time-lapse imaging, cells were incubated with Hoechst 
and Cell Mask Deep Red Plasma Membrane Stain (1:5000) for 5 min before washing with 
imaging medium and time lapse confocal microscopy. 
 
2.8 Labelling of lysosomes with dextran-Alexa647 
Cells were seeded to be 50-60% confluent on the day of dextran incubation. Dextran647 
(Dx647, 100 µg/ml) was incubated with cells for 2 h (5% CO2, 37°C), before washing with PBS 
and re-addition of complete cell culture media. Cells were then incubated for 18 h (5% CO2, 
37°C) before incubating with 50-60 µg/ml EV488 for colocalisation analysis. 
 
2.9 Incubation of cells with Endocytosis inhibitors 
All inhibitors were diluted from DMSO stocks to working solutions in imaging medium 
containing 0.05% BSA. Cells were seeded in 35 mm MatTek dishes 24 h before the day of the 
experiment to be 80-90% confluent. They were then washed three times with imaging 
medium containing 0.05% BSA and subjected to 30 min inhibitor pre-incubation with either 
Dynasore (80 µM), EIPA (25 µM), IPA-3 (50 µM) or Rottlerin (10 µM). Cells were then 
incubated with the stated concentration of experimental probe (Dx488/647, Tf488, EV488) 
for the specified time period in the continued presence of the inhibitor. They were then 
washed with imaging medium prior to performing live cell confocal microscopy. 
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2.10 siRNA depletion of proteins regulating endocytosis  
Performed as described in Supplementary Information. 
 
2.11 Internalisation of Tf488, Dx488/647 into cells 
Cells were seeded in 35 mm MatTek dishes and cultured for 24 h to be 80-90% confluent on 
the day of the experiment.  For transferrin uptake analysis, cells were washed three times 
and incubated with imaging medium supplemented with 0.05% BSA for 30 min before the 
addition of Tf488 (5 µg/ml) for 15 min. For dextran uptake, 100 µg/ml of Dx488/647 in 
imaging medium supplemented with 0.05% BSA was added to cells for 60 min without 30 
min pre-incubation.  Cells were incubated with Hoechst in imaging medium for 5 min before 
washing with fresh imaging medium followed by performing live cell confocal microscopy. 
 
2.12 SDS PAGE and Western blotting for siRNA depletion 
Performed as detailed in Supplementary Information 
 
2.13 Fluorescence Microscopy 
2.13.1 Live-cell imaging confocal microscopy 
Fluorescent images were taken using a Leica SP5 Confocal Microscope system and captured 
using LAS AF software. Cells were imaged at R/T with either a 40x 1.25 NA or a 63x 1.4 NA 
Oil Objective. Alexa488 was excited by a 488 Argon laser (20% intensity), and Alexa633/647 
excited by a 633 Helium-Neon laser (20% intensity). Bi-directional, sequential scanning was 
applied to ensure spectral separation of fluorophores. The presented movie was acquired 
using the same microscopy settings but with cells maintained at 37°C. 
2.13.2 Calculation of Colocalisation Coefficients 
 To determine the proportion of EVs (green fluorescence) associated with lysosomes (red 
fluoresĐeŶĐeͿ the Mϭ MaŶder͛s ĐoeffiĐieŶt ǁas calculated using the JaCop ImageJ plug-in 
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and thresholded using the automated default algorithm. Six fields of view (approximately 60 
cells) per time point were analysed and the mean calculated to provide an average 
colocalisation value for each repeat. The mean of the average colocalisation value for three 
separate experiments was plotted.  
2.13.3 Mean fluorescence intensity (MFI) quantification  
Individual cells from LAS AF files were manually selected as regions of interest (ROIs) using 
ImageJ software. Mean fluorescence intensity (MFI) of each was calculated, resulting in the 
quantification of approximately 150-160 cells per experimental sample. The geometric 
mean of each sample group was calculated to provide an average MFI for repeat 
experiments; the mean of the geometric mean from three independent experiments was 
calculated and used for statistical calculations.  
 
2.14 Statistical Analysis 
To Đoŵpare ĐoŶtrol treated saŵples agaiŶst eǆperiŵeŶtal saŵples, a StudeŶt͛s unpaired t-
test was utilised using the geometric mean of each separate experiment. Significance was 
specified as *p<0.05, **p<0.01, or ***p<0.001. 
3 Results and Discussion          
3.1 Characterisation and labelling of purified extracellular vesicles  
Cells produce a variety of debris and different types of vesicle, we therefore utilised our 
established approach for the specific isolation of EVs 37. Following the clearance of gross 
debris from cell-conditioned medium, by centrifugation (2000 x g), the medium were 
filtered (0.22 µm) to remove the majority of larger microvesicles. The medium was 
thereafter ultracentrifuged, capturing vesicles floating in an isotonic cushion of sucrose, 
preventing vesicles of classical densities 1.1-1.2 g/ml from pelleting.  
Cryo-electron microscopy was performed on EVs purified by this method, revealing the 
presence of genuine vesicle structures, with a lipid-bilayer boundary (Fig. 1A). There was 
some heterogeneity in sizes, and the structures are typical for EVs analysed by Cryo-EM as 
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reported 38. NaŶopartiĐle traĐkiŶg aŶalǇsis ;NTAͿ usiŶg the NaŶoSight™ platforŵ, reǀealed 
particulates with a modal hydrodynamic diameter of ~100 nm, and a low proportion of 
larger particulates (Fig. 1B), comparable to sizes seen by Cryo-EM. We also examined the 
preparation for the presence of proteins typically enriched in EVs. EV-preparations 
immobilised on microtitre plates were stained with antibodies specific for CD9, CD81, CD63 
and respective isotype-matched controls. 
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This highlighted strong, specific signals for these tetraspanins (Fig. 1C), which is a particular 
trait of exosomes39. In addition, by comparing the parent DU145 cancer cells with EV 
preparations by western blotting, we also reveal an enrichment of some classical EV-
associated proteins such as TGS101, Alix and MHC Class-I (Fig. 1C, inset). In contrast, the 
Fig.1. Labelling of EVs with malemide-Alexa488. (a) Cryo-electron microscopy of a typical 
preparation of DU145 EVs, with examples of small vesicular structures. Higher magnification 
micrographs highlight some heterogeneity in sizes. (b) Nanoparticle tracking analysis of DU145 
EV size distribution. (c) Plate-immobilised EVs with surface staining for tetraspanin proteins, as 
indicated.  (c, inset) western blot panel with cell lysates compared to EV lysates (each with 20 µg 
protein / lane), stained for exosomal or cellular markers as indicated. (d) Malemide-Alexa488 (5 
- 200 µg/ml) was incubated with EVs for 1 h prior to separation of free dye and analysis by 
fluorometry. (e) EVs were labelled with malemide-Alexa488 at 200µg/ml up to 3 h (circles) and 
retention of free dye by the column (squares). (f) EVs were pre-incubated with N-Acetyl-
Cysteine up to 1 mM for 30 min prior to labelling with malemide-488 (200 µg/ml for 1 h). (g) 
Malemide-Alexa488 labelled EVs analysed by NTA, (left) shows a similar size distribution profile 
measured in light scatter mode or measured with fluorescence filter revealing high proportion 
of fluorescent vesicles (middle); absence of fluorescent dye-particles in the absence of EVs 
(right). (h) Growth arrested fibroblasts were stimulated with treatments as indicated, and 72 h 
later fiǆed aŶd staiŶed for deteĐtioŶ of α-smooth muscle actin (red, Scale bar: 50 µm). (h, bars) 
Medium harvested from stimulated fibroblasts after 72 h, were assessed for levels of HGF by 
ELISA, showing mean ± Standard Deviation of triplicates. N/S: Not significantly different, n=3. (i) 
Primary lung fibroblasts were incubated with maleimide-633 labelled EVs (60 µg/ml) for 1 h 
before live cell confocal microscopy was performed. Cells were incubated with Hoechst for 5 
min before imaging to label the nucleus. Scale bar: 20 µm. 
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endoplasmic reticulum marker, Calnexin, was not detectable in these preparations, yet 
abundant in cell lysates, demonstrating the paucity of cellular contamination of these EV 
preparations. Furthermore, using a combination of BCA-protein assay and NanoSight™-
concentration measurements, the particle to protein ratio for purified EVs was calculated. 
This gives an indication of specimen purity as we describe 40 and for all preparations used in 
the study a particle : protein ratio of >2x1010 partiĐles/μg proteiŶ was achieved. 
The EV is an environment that is cysteine rich, through, for example, the presence of 
tetraspanin webs 39.  We therefore postulated that the thiol (-S-H groups) present on these 
structures would react with a maleimide functional group, to form a stable, non-reversible, 
thio-ether linkage. Fluorophore conjugated maleimides are often used to fluorescently label 
bio-molecules and here we used C5-maleimide conjugated to Alexafluor488. Other groups 
have exploited this labelling protocol in order to study micro-particle populations whereby 
whole blood samples were labelled with BODIPY-maleimide for analysis via flow cytometry 
41, 42.  However, BODIPY itself is used to label membranes, and is therefore likely to integrate 
onto the EV bilayer.  
We examined the capacity for maleimide-Alexa488 to react with EV thiols. Part of this 
procedure however, involves the removal of non-bound dye from the EV-preparations. 
Initial experiments used ultracentrifugation washes to achieve this, but the method was 
refined thereafter by using a spin-column (Invitrogen), that retains molecules of <3000Da. 
Initial experiments explored incubating a constant quantity of purified EVs with varying 
fluorophore concentrations (Fig. 1DͿ, shoǁiŶg saturatiŶg leǀels of laďelliŶg at ≥100 µg/ml 
after an incubation of 1 h. At the saturating fluorophore concentration 200 µg/ml, we also 
examined various incubation times revealing most of the fluorophore-EV labelling occurs 
very rapidly within the first 5 min, and saturation was reached at 1 to 2 h (Fig. 1E, circles). A 
control for fluorophore-only (no EVs) to assess its possible retention by the spin column is 
also shown, revealing negligible signal (Fig. 1E). We chose labelling conditions of 200 µg/ml 
for 1 h for the remainder of the study. To ascertain whether or not the fluorophore was 
actually forming a covalent bond through the thiol groups, or merely binding passively to 
the vesicle surface, we added a competitor that works by capping the available reactive thiol 
groups. Pre-incubating EVs with doses of N-acetyl-L-cysteine showed a potent (~80%) 
inhibition of labelling under these same conditions (Fig. 1F).  
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Nanoparticle tracking analysis revealed a similar size distribution profile following 
incubations with maleimide-Alexa488, suggesting a paucity of gross complexation due to 
maleimide-vesicle cross-linking (Fig. 1G, left). Importantly, NTA-analysis in the presence of a 
low-pass 500 nm filter showed the majority (>90%) of vesicles were fluorescent (Figure 1G, 
middle). The capacity to monitor fluorescent nanovesicles by this method is a challenge, and 
successful tracking here points to strong fluorescence output from each vesicle. We also 
analysed the stock maleimide-Alexa488 reagent, by NTA. Unlike for some other fluorescent 
labels, particularly PKH26, there were negligible particles detected in scatter mode, and 
there were no particles seen with a fluorescent filter in place (Figure 1G, right graph). An 
example of nanoparticulate PKH26 fluorescent aggregates in the absence of EVs are shown 
(Fig. S1). Particulate material spanning the size range of exosomes was present in the stock 
solution, and a high proportion (52%) of these are fluorescent. We conclude this method is a 
simple, rapid and highly effective modality for EV labelling, and is free of artefacts related to 
insoluble dye nanoparticulate. 
We next investigated the functional impact of coating EVs with our fluorescent label; an 
aspect that is rarely considered in previous studies. To do this, we relied on a well-
established functional assay whereby prostate cancer exosomes trigger the differentiation 
of fibroblasts to myofibroblasts 32. This process requires delivery of exosome-associated 
TGF to fibroblasts, but also is likely to involve additional exosome-cargo as the 
myofibroblasts generated are distinct from those formed by soluble TGF-stimulation in 
that secretion of Hepatocyte growth factor (HGF) is triggered 33. Stimulation of fibroblasts 
either with native or with maleimide-Alexa488 labelled EVs successfully triggered the onset 
of stress fibres visualized via SMA labelling; soluble TGFβ also did this as expected (Fig. 
1H). When evaluating the secretion of HGF however, there was clear difference in levels of 
HGF whether stimulations were by EVs or soluble TGFβ (Fig. 1H, bars), as we have previously 
observed 33. The labelled or unlabelled EVs were equally proficient at stimulating HGF 
secretion. 
In this assay, which represents a major and complex cell differentiation process, our 
maleimide-Alexa488 labelling approach shows no signs of attenuating EV function.  
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3.2 Endocytic analysis of Alexa488 extracellular vesicles in cells  
We investigated the possibility of visualising the labelled EVs following incubation with the 
fibroblasts.  These cells had high background cellular autofluorescence at 488nm excitation 
(Data not shown) and the purified EVs were therefore labelled with Alexa633 using the 
same procedure. Fig. 1I demonstrates these EVs were internalised to label punctate 
structures indicative of endosomes. These cells are however poorly characterised with 
respects to characterisation of endocytosis. We and others have performed detailed studies 
of the involvement of individual endocytic pathways in HeLa cells as model for uptake of 
drug delivery vectors 34. Previous studies on exosome and EV uptake have also been 
published using HeLa cells 30, 43, 44. We therefore decided to focus our subsequent 
experiments on the well characterised HeLa cell line. 
HeLa cells incubated with Alexa488 labelled EVs (EV488) for 30 and 60 min demonstrated a 
scattered punctate distribution throughout the cell cytoplasm (Fig. 2A). Time lapse imaging 
of EV488 incubated with HeLa cells over a period of 3 min (after a 120 min pre-incubation) 
shows these structures to be highly motile with little evidence of extensive accumulation at 
the plasma membrane (Video. S1). There was a noticeable time dependant increase in 
fluorescence intensity from 30 min to 240 min (Fig. 2B) and at this later time point 
fluorescence was more polarised to the perinuclear regions. This confirmed that these 
labelled EVs also have endocytic capacity in this cell line, allowing further analysis of cell 
entry mechanisms. 
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3.3 Traffic of Alexa488 extracellular vesicles to lysosomes 
Cells incubated with EVs for >60 min showed the accumulations of fluorescence in the 
perinuclear region suggesting a fraction were being trafficked to lysosomes that are also 
prominent in this region in HeLa cells (Fig. 2) 45. EV traffic from the plasma membrane was 
then studied at different time points in cells containing labelled lysosomes via a pulse-chase 
incubation. Colocalisation between 488-EVs and 647-lysosomes was barely detected at 30 
min and then increased over a period of six hours to the point that after 360 min ~60% of 
detected EVs were contained in labelled lysosomes (Fig. 3). This method measures the 
location of EVs in early and late endocytic compartments including lysosomes.  We then 
performed experiments by which dextran was similarly used to label lysosomes but 
following a two hour pulse of EV endocytosis the cells were washed and the material 
already associated with the cells was chased for a further 4 hour revealing that over 60% of 
EV associated labelling had reached and remained at the lysosomes by the end of this chase 
period (Fig. S2).  
 
Fig.2. Time dependent EV endocytosis in HeLa cells. (a) Cells were incubated with EV488 (60 
µg/ml) for 30, 60, 120 or 240 min and incubated with Hoechst for 5 min before live cell confocal 
imaging. Scale bars: 20 µm. Images representative of three separate experiments. (b) MFI 
quantification of the experiments presented. Error bars: Standard error. Representative of three 
separate experiments. 
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3.4 Endocytic Uptake of Extracellular vesicles in Clathrin-mediated endocytosis (CME) 
Compromised Cells 
CME has been extensively characterised in in vitro models including HeLa cells 10, 11, and this 
process can be attenuated using a range of methods 34. These include siRNA depletion of a 
key member of the of the CME adaptor complex AP2, known as AP2µ2 or AP50. This subunit 
is essential for the anchorage of cargo at the plasma membrane and subsequent 
recruitment of clathrin and further regulatory proteins to allow the process of 
internalisation to proceed 46. We and others have shown that siRNA depletion of AP2µ2 
prevents the uptake of transferrin via the transferrin receptor 45, 47. Following a 48 hour 
transfection with siRNA the AP2µ2 protein (50 kDa) was effectively depleted versus a 
Fig.3. Co-localisation of 488-labelled EVs with dextran-loaded lysosomes in HeLa cells. (a) Cells 
were incubated with Dx647 (100 µg/ml) for 2 h, washed with PBS and incubated for a further 18 
h in culture media. Cells were then incubated with EV488 (60 µg/ml) for either 30, 60, 120 or 
360 min before treatment with Hoechst for 5 min and live cell confocal imaging. Solid 
arrowheads indicate colocalisation between EVs and lysosomes and transparent arrowheads 
indicate EVs not colocalised with lysosomes. Scale bars: 20 µm and 10 µm in zoomed images. 
Iŵages represeŶtatiǀe of three separate eǆperiŵeŶts. ;ďͿ MaŶder͛s ĐorrelatioŶ ĐoeffiĐieŶt 
analysis of the proportion of green fluorescence (EVs) associated with far-red fluorescence 
(lysosomes) based on the experiments performed to generate Fig 3A. Error bars: Standard error. 
Representative of three separate experiments. 
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control siRNA (Fig. 4A). A second siAP2µ2 insensitive lower molecular weight band was 
identified with this antibody that was insensitive to siRNA AP2µ2, this has previously been 
shown but not explained 48. In these siAP2µ2 treated cells incubated with Tf488 for 15 min, 
the probe was mainly sequestered at the plasma membrane compared to internalised 
punctate structures in control cells (Fig. 4B). si-control and AP2µ2 depleted cells were also 
incubated with EV488 for 60 min prior to analysing cell fluorescence. Fig. 4C shows no 
noticeable difference in either the cell fluorescence or the distribution of vesicular labelling 
between these two conditions. This was further confirmed by quantification of the mean 
fluorescence intensity (MFI) from three separate analyses including cells that were not 
transfected (Fig. 4D).  
Extracellular vesicle uptake was also evaluated in cells treated with a widely used dynamin II 
inhibitor, Dynasore, previously used in numerous studies to evaluate the uptake of different 
entities via dynamin-dependant endocytic processes, such as CME and caveolae 49. Cells 
were pre-incubated with Dynasore for 30 min prior to addition of Tf488 for 15 min or EV488 
for 60 min. Both the confocal microscopy images and MFI data highlight the strong 
inhibition of Tf488 uptake by this drug (Fig. 4E-F). Unlike the AP2µ2 phenotype showing 
strong Tf488 labelling on the plasma membrane, Dynasore treated cells were almost devoid 
of any labelling; the reason for this is currently unknown but suggests that Tf is unable to 
access its receptor in Dynasore treated cells. There was a much smaller but significant 
decrease in EV uptake in Dynasore treated cells (Fig. 4E-F). This observation shows that a 
significant proportion of EVs are entering via a dynamin II-dependant mechanism that based 
on data in Fig. 4C is not CME. Interestingly cells transfected with a dominant negative 
dynamin II mutant were also shown to have reduced exosome uptake in RAW 264.7 
macrophages 23. Our observation of EV uptake, by a Dynasore but not an AP2µ2 dependent 
process, could be due to the fact dynamin II has been implicated in the regulation of other 
endocytic pathways such as fluid-phase uptake and caveolae 50, 51. Furthermore, it has 
recently been demonstrated that Dynasore elicits additional dynamin independent effects 
on the cholesterol organisation of plasma membrane lipid rafts 52. Alteration of the plasma 
membrane in this way could affect the wider endocytic network, thereby affecting the 
designated uptake route of these structures. These studies led to further investigations 
targeting other endocytic proteins and pathways.  
18 
 
  
3.5 Extracellular vesicle uptake in Caveolin-1 and Flotillin-1 depleted cells 
Using the same siRNA-based approach, both Caveolin-1 and Flotillin-1 proteins were 
successfully depleted but the loss of these proteins, and the endocytosis that they organise, 
did not significantly affect cellular uptake of the labelled EVs (Fig. 5). Although not 
Fig.4. Internalisation of EVs in CME compromised HeLa cells. (a) Western blot analysis of AP2µ2 
protein levels 48 hr following siRNA transfection in comparison with loading GAPDH loading 
control. (b) Cells were depleted of either AP2µ2 via siRNA transfection for 48 h before 
incubation with either (b) Tf488 (5 µg/ml) for 15 min or (c) EV488 (50 µg/ml) for 60 min. White 
arrowheads indicate surface bound Tf488. (e) Cells were pre-incubated with Dynasore (80 µM) 
for 30 min before incubation with either Tf488 (5 µg/ml) for 15 min or EV488 (50 µg/ml) for 60 
min. All were incubated with Hoechst for 5 min before live cell imaging. Scale bars: 20µm. 
Images representative of three separate experiments. (d), (f) MFI quantification of the 
experiments presented in (c), (e), respectively. Utx: Untransfected. Error bars represent 
Standard error. *p<0.05, ***p<0.001, n/s: No significance. Representative of three separate 
experiments. 
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performed for the studies presented here, we and others have however shown that 
endocytosis of lactosyl-ceramide and an anti-CD59 antibody have previously been shown to 
be reduced, respectively, in Caveolin-1 and Flotillin-1 depleted cells 34, 53. It should be noted 
that depletion of either of these proteins could have significant cellular effects beyond that 
of reducing endocytic processes as both have been implicated as important modulators of 
cell signalling and organisation of lipid rafts 54. Of interest is that the distribution of EV 
labelling was more peripheral in siRNA Flotillin-1 cells compared with controls suggesting 
alterations in downstream endocytic traffic. Overall these observations strongly suggest that 
endocytic processes involving Caveolin-1 and Flotillin-1 are not the primary mode of EV 
entry. 
 
 
Fig.5. Internalisation of EVs in HeLa 
cells depleted of Cav-1 and Flot-1. (a) 
Western blot analysis of Cav-1 and 
Flot-1 protein levels in HeLa cells 48 
h following siRNA transfection in 
comparison with loading proteins 
Tubulin or GAPDH. (b) Cells were 
depleted of either Cav-1 or Flot-1 via 
siRNA transfection for 48 h before 60 
min incubation with EV488 (50 
µg/ml). Cells were incubated with 
Hoechst for 5 min before live cell 
imaging. Scale bar: 20 µm. Images 
representative of three separate 
experiments. Arrowheads in B 
represent peripheral EVs (c) MFI 
quantification of the experiments 
presented in (b). Utx: Untransfected. 
Error bars represent Standard error. 
n/s: No significance. Representative 
of three separate experiments. 
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3.6 Extracellular vesicle uptake in cells depleted of proteins regulating actin dynamics, 
fluid-phase endocytosis and macropinocytosis  
Fluid-phase endocytosis could be viewed as a process of constitutive plasma membrane 
turnover performed important for functions such as nutrient gathering and sampling of the 
extracellular environment. Macropinocytosis has been described as a mechanism that is 
activated upon growth factor stimulation and could be conceived as an activated form of 
fluid-phase endocytosis 14, 15, 55, 56. Both lack a specific master regulatory protein that could 
be targeted for siRNA depletion without affecting other processes. Macropinocytosis is 
highly reliant upon the organisation of actin, thus actin regulating proteins are candidate 
siRNA targets for inhibition of this process. Actin may also have involvement in constitutive 
fluid phase uptake 57. The p21-activated kinases (PAKs) regulate numerous modifications of 
the cytoskeleton, particularly through their interactions with the Rho GTPases, Cdc42 and 
Rac1 58, 59. PAK-1 has been identified as an important regulatory factor in the events 
associated with macropinocytosis 18, 19. Cells were successfully transfected with siRNA 
sequences targeting PAK-1 and Cdc42 (Fig. 6A) to investigate the roles of these proteins on 
initially the uptake of dextran that represents in the absence of growth factor activation, a 
constitutive fluid phase probe 60, 61. Our previous studies indicated that PAK-1 was involved 
in the cellular uptake of cationic cell penetrating peptides that may be inducing a form of 
macropinocytosis for cell entry 34, 62. Despite some visual evidence of a reduction of dextran 
uptake in PAK-1 depleted cells (Fig. 6B), quantitative analysis showed that this was not 
significant and no effects were also noted for Cdc42 depletion (Fig. 6C). Following a 60 min 
endocytic pulse in the cells depleted of either PAK-1 or Cdc42 (Fig. 6D), a small but 
insignificant decrease (Fig. 6E) in EV uptake was observed. Localisation of punctate EV 
structures in Cdc42 depleted cells was noticeably different from control cells, being much 
more apparent at the cell periphery suggesting an inability of these structures to be 
trafficked beyond the plasma membrane region (Fig. 6D). These observations are further 
represented in the additional fields of view presented in Fig. S3. As noted for Flotillin-1 and 
Caveolin-1 the effects of depleting these proteins scope wider than endocytosis but the data 
suggest that traffic of EVs beyond the plasma membrane is regulated by Cdc42 and most 
probably actin. Actin regulating agents such as Cytochalasin D are routinely used to monitor 
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the involvement of actin on endocytosis but they also cause gross morphological effects on 
cells (data not shown) making data interpretation very difficult. 
 
Fig.6. Internalisation of EVs in HeLa cells depleted of fluid-phase/macropinocytosis related 
proteins. (a) Western blot analysis of Cdc42 and PAK-1 protein levels in cells 48 h following 
siRNA transfection in comparison with loading proteins Tubulin or GAPDH. (b) Cells were 
depleted of either Cdc42 or PAK-1 via siRNA transfection for 48 h before 60 min incubation with 
either (b) Dx488 (100 µg/ml) or (d) EV488 (50 µg/ml). Cells were incubated with Hoechst for 5 
min before live cell imaging. Arrowheads in D represent peripheral EVs. Utx: Untransfected. 
Scale bar: 20 µm. Images representative of three separate experiments, respectively. (c), (e) MFI 
quantification of the experiments presented in (b), (d), respectively. Error bars represent 
Standard error. n/s: No significance. Representative of three separate experiments, respectively. 
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3.7 Extracellular vesicle uptake in cells treated with fluid-phase/macropinocytosis 
inhibitors  
Endocytosis inhibitors can be used in conjunction with siRNA transfection studies to provide 
a more comprehensive analysis of the endocytic uptake of different probes 53. Following our 
observations in siPAK-1 and siCdc42 cells, inhibitors targeting fluid-phase endocytosis and 
macropinocytosis were utilised to further explore the involvement of these pathways in EV 
uptake. 
5-(N-Ethyl-N-isopropyl) amiloride (EIPA) is a commonly utilised Na+/H+ exchange inhibitor, 
and most probably prevents macropinocytosis by lowering the submembranous pH of the 
macropinocytic cup 63. A small but insignificant (p=0.61) decrease in dextran uptake was 
observed in EIPA treated cells (Fig. 7A-B), suggesting that it has little effect on fluid-phase 
endocytosis. Transferrin internalisation in these cells in comparison with control treated 
cells was significantly reduced, indicating that EIPA affects CME to a certain degree (Fig. S4). 
Notably, differences in the localisation of transferrin loaded vesicles was apparent, agreeing 
with our previous studies showing effects on the subcellular localisation of early and late 
endosomes/lysosomes in cells treated with this drug 64. Previous studies in PC12 cells 
incubated with self-derived exosomes have shown by flow cytometry that EIPA significantly 
reduces uptake of DiD labelled PC12 exosomes 26. In our study EIPA cells caused a small but 
insignificant decrease in EV uptake (Fig. 7C-D). Rottlerin is an inhibitor primarily utilised to 
target fluid-phase endocytosis rather than macropinocytosis 61. Its effects have previously 
been connected with inhibition of PKCδ activity 65, though other Rottlerin targets have been 
identified 66, 67. Rottlerin did not affect the uptake of dextran but was a significant inhibitor 
of Tf and EV uptake in these cells (44% and 51% respectively) (Fig. 7 and S4). The PAK-1 
inhibitor IPA-3 68, has previously been used to propose macropinocytosis as a mechanism for 
viral cell entry  69, 70. This drug induced a significant decrease in dextran uptake (60%) and 
EVs (50%, Fig. 7) with Tf488 showing a slight, non-significant decrease. However, Tf488 
localisation was more scattered in treated cells (Fig. S4) with a concomitant loss of 
juxtanuclear polarisation that is indicative of the localisation of Tf recycling compartments in 
this cell line. Collectively observations with these inhibitors suggest that a major fraction of 
EVs enter cells by fluid phase endocytosis rather than macropinocytosis.  
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4 Conclusions 
Here we describe an efficient and novel method to fluorescently label EVs characterised as 
exosomes for subsequent high content microscopy analysis of their interactions with cells 
Fig.7. Internalisation of EVs in HeLa cells treated with fluid-phase/macropinocytosis inhibitors. 
(a,c) Cells were pre-incubated with EIPA (25 µM), Rottlerin (10 µM), IPA-3 (50 µM), or 0.05% 
DMSO as ͚Pos Ctrl͛ for ϯϬ ŵiŶ ďefore ϲϬ ŵiŶ iŶĐuďatioŶ ǁith either ;aͿ Dǆϰ88 ;ϭϬϬ µg/ŵlͿ or ;ĐͿ 
EV488 (50 µg/ml). Cells were incubated with Hoechst for 5 min before live cell imaging. Scale 
bar: 20 µm. Images representative of three separate experiments. (b), (d) MFI quantification of 
the experiments presented in (a), (c), respectively. Error bars represent Standard error. *p<0.05. 
n/s: No significance. Representative of three separate experiments. 
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and endocytic traffic. Unlike other current labelling methods, this technique provides 
flexibility with regards to choice of fluorophore used and also provides the ability to easily 
label EVs from different cell types. In the case of prostate cancer DU145 derived EVs the 
labelling procedure did not affect their capacity to induce complex cellular responses such 
as fibroblast to myofibroblast differentiation and induction of HGF secretion. It however 
remains to be determined whether this labelling method influences the other numerous 
functional effects documented for EVs. It will also be interesting to compare our data with 
exosomes labelled using the same procedure but with different fluorophores, noting that 
they have unique characteristics that could affect cell uptake 71 and differentiation. 
Interference of endocytic pathways with inhibitors and siRNA depletion of endocytosis 
mediators together with endocytic trafficking studies strongly suggest our EVs enter cells as 
components of the extracellular fluid and like dextran are mostly trafficked to lysosomes. 
Approximately 40% of endocytosed EVs however are not fated for lysosomes, at least within 
the time-frame that we have explored. The implications of these endocytosis characteristics 
for the use of EVs as drug delivery vectors remain to be determined but their trafficking 
profiles may be beneficially exploited if they can be packaged with small molecule drugs for 
lysosomal release into the cytosol. 
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Supplementary Materials 
 
Supplementary Materials and Methods 
 
1. Extracellular vesicle (EV) isolation, purification and characterisation 
Extracellular vesicles were purified from 7-day cell conditioned media, pre-cleared of 
cell debris and microvesicles by differential centrifugation followed by filtration 
through a 0.22 µm filter (Millipore).  EVs were purified based on their density by 
ultracentrifugation at 100,000 x g on a 30% sucrose/D2O cushion as described 1. 
Purified EVs were resuspended in around 100 µl PBS, aliquoted, before storage at -80°C. 
Total protein was quantified by microBCA protein assay (ThermoFisher Scientific, 
Paisley, UK). The number, and size distribution of nano-particles was assessed by 
nanoparticle tracking analysis (Nanosight; Malvern Instruments, Worcestershire, UK). 
As a measure of EV purity, protein and nanoparticle concentrations were used to 
calculate a ratio of particle to protein. All preparations had a particle to protein ratio of 
>2x1010 particles per μg of protein, as described 2. The presence of tetraspanins at the 
outer EV surface was determined using a plate-immobilisation of purified EVs, and 
indirect staining with antibodies against CD9 (R&D Systems, Abingdon, UK), CD81 or 
CD63 (BioRad, Hertfordshire, UK), a secondary anti-Mouse IgG-biotin conjugate 
(PerkinElmer) and streptavidin-Europium detection. Primary antibodies against 
relevant isotypes, IgG1 and IgG2b (eBioscience, ThermoFisher Scientific), were used as 
a control. Time resolved fluorometry was performed on a Pherastar FS instrument 
(BMGlabtech, Germany) as described 3. Whole cell lysates, prepared using RIPA-buffer 
(Santa Cruz Biotechnology) were compared to EV lysates, prepared by boiling in SDS-
sample buffer containing 20 mM DTT, by western blotting running 10 µg protein per 
lane. After transfer to PVDF membranes (GE Healthcare), and blocking with 5% non-fat 
powdered milk with 0.1% Tween-20 in PBS for 1 hr, primary monoclonal antibody at a 
concentration of 1-4 µg/ml was added at 4°C overnight. Antibodies for expected EV 
proteins TSG101, Alix, LAMP1 (Santa Cruz Biotechnology), MHC Class I (eBioscience, 
ThermoFisher Scientific) were used, and to assess cellular contaminants, blots were 
also probed for calnexin expression (Santa Cruz). After washes in 0.1% Tween-20/PBS 
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bands were detected using an anti-mouse IgG-horseradish peroxidase conjugated 
antibody (Santa Cruz) and chemiluminescence substrate (PicoWest, ThermoFisher 
Scientific). Images of membranes were collected using the C-DiGit Chemiluminescence 
Blot Scanner (LI-COR Biotechnology, Cambridge, UK). 
 
2. Extracellular vesicle analysis by Nano particle Tracking Analysis ȋNanoSight™Ȍ 
Freshly prepared EVs, or those following fluorescent labelling were diluted in particle 
free water (Fresenius Kabi, Runcorn, UK) to concentrations up to 2x109 particles/ml, 
which is within the linear range of the NanoSight instrument. Analysis was performed on a NanoSight™ NS͵ͲͲ system configured with a temperature controlled LM14 laser 
module with a 488 nm laser and a high sensitivity sCMOS camera system and a syringe-
pump system (Malvern Instruments, Malvern, UK). Three videos of 30-60 s were taken 
under controlled fluid flow with a pump speed set to 80, and temperature set to 25°C. 
Videos were taken in light scatter mode. On some occasions, videos were also taken 
following application of a long-pass fluorescence filter, so that only particles emitting 
light at >500 nm were visible.  This required corrections for focusing, and an adjustment 
to the camera settings to maximise chances of visualising, and tracking fluorescent 
nano-particles. Videos were analysed using the batch analysis tool of NTA 2.3 software 
(version 2.3 build 2.3.5.0033.7-Beta7), where minimum particle size, track length and blur were set at ǲautomaticǳ. The area under the histogram for each triplicate 
measurement was averaged and used as a particle concentration measurement. 
 
3. Cryo-electron microscopy of purified extracellular vesicles 
Extracellular vesicle preparations were adsorbed onto glow-discharging holey carbon 
200-mesh copper grids (Quantifoil Micro Tools GmbH). Grids were vitrified with the aid 
of a Vitrobot (Maastricht Instruments BV). Vitrified samples were imaged at liquid 
nitrogen temperature using a JEM-2200FS/CR transmission cryo-electron microscope 
(JEOL) equipped with a field emission gun and operated at an acceleration voltage of 
200 kV. 
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4. siRNA transfection 
In a 6 well plate (or 35 mm imaging dish) 100 pmols siRNA was diluted in 185 µl Opti-
MEM while in a separate container 2 µl Oligofectamine was diluted with 13 µl OptiMEM. 
The two solutions were gently mixed and incubated at room temperature for 30 min. 
The cells were washed with Opti-MEM and 800 µl of Opti-MEM was added before 
dropwise addition of the siRNA complex mixture. Cells were returned to the incubator 
for 4 h before addition of 500 µl Opti-MEM containing 30% FCS and incubated for 44 h. 
 
5. SDS PAGE and Western blotting 
5.1. Following siRNA depletion 
Following 48 h transfection, cells were washed with PBS followed by incubation on ice 
for 5 min in 100 µl ice-cold lysis buffer - 150 mM NaCl, 50 mM Tris-base pH 8.0, 1% 
Triton X-100 containing protease inhibitor cocktail. Cells were scraped from the plastic 
surface, placed in eppendorf tubes and then centrifuged for 10 min (13000 x g) at 4°C. 
The protein concentration of each sample was calculated via BCA assay and 18 µg 
protein per sample was mixed with 3x SDS PAGE sample buffer, heated to 95°C and 
loaded on to 8%, 10% or 12% SDS-PAGE gels. Following gel electrophoresis, proteins 
were transferred to PVDF membranes before blocking (5% w/v dried milk in PBS 
0.0025% v/v Tween 20 (PBSTM)) and incubation with primary antibodies recognising 
AP2µ2, Caveolin-1 (Cav-1), Cdc42, Flotillin-1 (Flot-1), p21-activated kinase-1 (PAK-1), 
or GAPDH in 2% PBSTM. Secondary antibody incubation with goat anti-rabbit HRP 
conjugate, goat anti-mouse HRP conjugate or HRP conjugated anti-δ-tubulin was then 
performed and chemiluminescence was detected on a ChemiDoc imager using ImageLab 
software (Bio-Rad).   
 
6. Optimisation and characterization of extracellular vesicle labelling 
C5-maleimide-Alexa488 (5-ʹͲͲ μg/mlȌ was added to a ͵Ͳ μl EV aliquot containing 60 to ͳͲͲ µg protein, and made up to a final volume of 5Ͳ μl with PBS.  )ncubations, with no 
agitation, for 60 min in the dark at room temperature (R/T), were followed by removal 
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of unbound dye using exosome spin columns ȋ)nvitrogenȌ according to manufacturerǯs 
instructions. Collected labelled EVs were added to black-walled 96-well plates and the 
average fluorescence of triplicate wells measured on a PHERAstar FS plate reader (BMG 
Labtech, Ortenberg, Germany). Similarly, at a fixed dose of 200 µg dye, incubations for up 
to 3 h were performed before assessing intensity of labelling. In parallel, dye in the 
absence of EVs were included in these experiments, to assess the efficacy of free-dye 
capture by the exosome spin columns. For some experiments, the free sulph-hydryl 
bonds at the EV surface were capped by pre incubations with N-acytyl-L-cysteine (up to 
1 mM) for 30 min prior to dye labelling (200 µg/ml, 1 h) and fluorescence assessment; 
revealing approximately 80% inhibition of labelling at maximal N-acetyl-L-cysteine 
dose. 
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Supplementary Figures 
 
Supplementary Figure. 1. PKH26 
dye was diluted 1 in 1000 in the 
provided dilution buffer, and 
analysed by NTA. The analysis 
was performed in light scatter 
mode (grey), and then following 
application of fluorescence filter 
where only fluorescing particles 
are visible (black, dashed line). 
We conclude that small 
particulate material spanning 
the size range of EVs is present 
in the stock solution, and a 
proportion (52%) of these are 
fluorescent. 
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Supplementary Figure. 2. Colocalisation of 488-labelled extracellular vesicles with 
dextran-loaded lysosomes in HeLa cells. Cells were incubated with Dx647 (100 µg/ml) 
for 2 h, washed with PBS and incubated for a further 18 h in culture media. Cells were 
then incubated with EV488 (60 µg/ml) for 2h with no chase or for 2 h followed by 
washing and a 4 hr chase. Scale bars: 20 µm and 10 µm on zoomed images. Images 
representative of three separate experiments. 
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Supplementary Figure. 3. Additional fields of view showing internalisation of 
extracellular vesicles in HeLa cells depleted of fluid-phase/macropinocytosis related 
proteins. Cells were depleted of either Cdc42 or PAK-1 via siRNA transfection for 48 
h before 60 min incubation with EV488 (50 µg/ml). Cells were incubated with 
Hoechst for 5 min before live cell imaging. Utx: Untransfected. Scale bar: 20 µm. 
Images representative of three separate experiments. 
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Supplementary Figure. 4. Transferrin internalisation in HeLa cell models of fluid-
phase/macropinocytosis inhibition. (a) Cells were depleted of either Cdc42 or PAK1 
via siRNA transfection for 48 h, or (c) pre-incubated with either EIPA (25 µM), 
Rottlerin (10 µM), IPA-͵ ȋ5Ͳ µMȌ, or Ͳ.Ͳ5% DMSO as ǮPos Ctrlǯ for ͵Ͳ min before ͳ5 
min incubation with Tf488 (5 µg/ml). Cells were incubated with Hoechst for 5 min 
before live cell imaging. Scale bar: 20 µm. Images representative of three separate 
experiments. (b) and (d) MFI quantification of the experiments presented in (a) and 
(c), respectively. Error bars represent Standard error. *p<0.05, **p<0.01. 
Representative of three separate experiments. 
Supplementary Video.1. Time lapse images of EV488 uptake in HeLa cells. EV488 
(60 µg/ml) were added for a period of either 120 min before confocal time lapse 
imaging. Hoechst and cell mask deep red were added for the final 5 min before 
imaging. Imaging was continuously performed for a period of 2 min. 
